Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Topical and systemic treatments for blepharokeratoconjunctivitis in children

Poster Details

First Author: M. O'Gallagher UNITED KINGDOM

Co Author(s):    M. Banteka   C. Bunce   M. Hingorani   F. Larkin   S. Tuft   A. Dahlmann-Noor     

Abstract Details


To assess and compare data on the efficacy and safety of topical and systemic treatments, alone or in combination, for blepharokeratoconjunctivitis (BKC) in children aged 0 to 16 years, including antibiotics, steroids, immunosuppressants and lubricants.


Systematic review searching the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to present), EMBASE (January 1980 to present), the ISRCTN registry, and the World Health Organization International Clinical Trials Registry Platform (ICTRP).


We performed a systematic review of the literature for randomised controlled trials involving topical and systemic treatments in children aged 0 to 16 years with a clinical diagnosis of BKC. Two authors independently screened the results of the search (titles and abstracts) to identify studies that loosely met the inclusion criteria of the review. We divided studies into 'definitely include', 'definitely exclude' and 'possibly include' categories. We made a final judgement as to the inclusion/exclusion of those in the 'possibly include' category after obtaining the full copy of each article.


No report or trial fully met the inclusion criteria for this review.


There is no high-quality evidence of the safety and efficacy of topical or systemic treatments for BKC, resulting in uncertainty about indications and effectiveness of treatment. Clinical trials are required to test efficacy and safety of current and any future treatments. Outcome measures need to be developed which can capture both objective clinical and patient-reported aspects of the condition and treatments.

Financial Disclosure:


Back to Poster listing